BACE2 as a new diabetes target: a patent review (2010 – 2012)

Introduction: When two novel aspartyl proteases were published in 1999 and 2000, beta-site APP-cleaving enzyme 1 (BACE1) was confirmed as the long sought after beta-secretase and Alzheimer's disease drug target. However, the role of its paralogue, BACE2, proved elusive until a 2011 publication implicated it as a Collectrin (TMEM27) secretase controlling pancreatic beta-cell proliferation and a new therapeutic intervention for diabetes. Areas covered: This review, using SureChemOpen, encompasses early validation compounds and small-molecule BACE2 inhibitors for diabetes. Since 2010, one assay patent and several chemical series have been published by Roche but these were followed by filings from Novartis and Schering in 2012. The patents from these three companies include BACE2-only filings but also some specifying both BACE1 and BACE2 inhibitors. Expert opinion: Roche's early collaborative target validation has given them a lead in BACE2 medicinal chemistry. However, the extensive data output for BACE1 in patents and papers over the last decade, plus liganded crystal structures for both proteases, should expedite the design of BACE2 inhibitors by other organisations. This may also shorten the development time for clinical candidates that, unlike those now entering Phase I trials for BACE1, would not need to be brain-penetrant.

[1]  C. Haass,et al.  BACE1 dependent neuregulin processing: review. , 2012, Current Alzheimer research.

[2]  Leandro Martínez,et al.  Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists , 2012, PloS one.

[3]  C. Schnitzler,et al.  BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein , 2000 .

[4]  M Katharine Holloway,et al.  Conformationally biased P3 amide replacements of beta-secretase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[5]  M. Stoffel,et al.  Tmem27 dimerization, deglycosylation, plasma membrane depletion, and the extracellular Phe-Phe motif are negative regulators of cleavage by Bace2 , 2012, Biological chemistry.

[6]  J. Tang,et al.  Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[8]  C. Schnitzler,et al.  BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Luchsinger.  Type 2 diabetes and cognitive impairment: linking mechanisms. , 2012, Journal of Alzheimer's disease : JAD.

[10]  R. Gomis,et al.  BACE2 plays a role in the insulin receptor trafficking in pancreatic ß-cells. , 2010, American journal of physiology. Endocrinology and metabolism.

[11]  R. Aebersold,et al.  Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass. , 2011, Cell metabolism.

[12]  C. Southan,et al.  Identification of a novel aspartic protease (Asp 2) as beta-secretase. , 1999, Molecular and cellular neurosciences.

[13]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[14]  Rudi D'Hooge,et al.  Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient Mice* , 2005, Journal of Biological Chemistry.

[15]  F. Acquati,et al.  BACE2 is Stored in Secretory Granules of Mouse and Rat Pancreatic β Cells , 2008, Ultrastructural pathology.

[16]  N. Ostermann,et al.  Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor. , 2006, Journal of molecular biology.

[17]  Arun K. Ghosh,et al.  Developing β‐secretase inhibitors for treatment of Alzheimer’s disease , 2012, Journal of neurochemistry.

[18]  F. Acquati,et al.  The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the Down critical region , 2000, FEBS letters.

[19]  C. Haass,et al.  BACE1 Dependent Neuregulin Proteolysis. , 2011, Current Alzheimer Research.

[20]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[21]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[22]  D. Leroith,et al.  The worldwide diabetes epidemic , 2012, Current opinion in endocrinology, diabetes, and obesity.

[23]  Sorel Muresan,et al.  Analysis of in vitro bioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds , 2011, J. Cheminformatics.

[24]  Ying-zi Xu,et al.  Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011) , 2012, Expert opinion on therapeutic patents.

[25]  Jennifer Williamson,et al.  Rare Variants in APP, PSEN1 and PSEN2 Increase Risk for AD in Late-Onset Alzheimer's Disease Families , 2012, PloS one.

[26]  C. Southan,et al.  ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. , 2000, Molecular and cellular neurosciences.

[27]  M. Leissring,et al.  Identification of BACE2 as an avid ß-amyloid-degrading protease , 2012, Molecular Neurodegeneration.

[28]  Jan Krützfeldt,et al.  Tmem27: a cleaved and shed plasma membrane protein that stimulates pancreatic beta cell proliferation. , 2005, Cell metabolism.

[29]  Christopher Southan,et al.  InChI in the wild: an assessment of InChIKey searching in Google , 2013, Journal of Cheminformatics.

[30]  J. Speakman,et al.  Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice , 2011, The Biochemical journal.

[31]  C. Haass,et al.  Loss of Bace2 in zebrafish affects melanocyte migration and is distinct from Bace1 knock out phenotypes , 2013, Journal of neurochemistry.

[32]  Suphia M Sherbeeni,et al.  Pharmacological management of type 2 diabetes mellitus: an update. , 2011, Current diabetes reviews.